SEC Form 4 · accession 0001209191-19-004601
TETRAPHASE PHARMACEUTICALS INC · TTPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jacques Dumas
Officer — Chief ScientificOfficer
Period of report
Jan 17, 2019
Accepted (ET)
Jan 18, 2019 · 6:00 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001373707
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitF1,F2 | — | Jan 17, 2019 | A | 40,000 | A | — | — | Common Stock | 40,000 | 40,000 | D |
| Restricted Stock UnitsF1,F3 | — | Jan 17, 2019 | A | 140,000 | A | — | — | Common Stock | 140,000 | 140,000 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of common stock of Tetraphase Pharmaceuticals, Inc. for no consideration.
- F2These restricted stock units shall be eligible to vest upon achievement of certain performance conditions and, if such conditions are met, shall vest on various dates beginning no earlier than March 1, 2020 and ending no later than March 1, 2022.
- F3The restricted stock units vest in three equal installments on each of January 17, 2020, January 17, 2021 and January 17, 2022.